Iovance Biotherapeutics, Inc.
IOVA
$6.98
$0.467.06%
NASDAQ
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 297.67M | 313.44M | 296.98M | 300.80M | 301.18M |
| Total Receivables | 102.12M | 81.76M | 82.45M | 66.76M | 59.94M |
| Inventory | 55.59M | 58.38M | 51.68M | 51.71M | 49.83M |
| Prepaid Expenses | 8.87M | 12.93M | 11.58M | 9.82M | 11.55M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | -- | -- | -- | -- | -- |
| Total Current Assets | 464.26M | 466.50M | 442.69M | 429.09M | 422.50M |
|
|
|||||
| Total Current Assets | 464.26M | 466.50M | 442.69M | 429.09M | 422.50M |
| Net Property, Plant & Equipment | 174.94M | 175.78M | 177.01M | 175.41M | 172.42M |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | 263.89M | 269.10M | 279.32M | 285.21M | 296.25M |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 12.44M | 14.28M | 14.15M | 15.24M | 16.26M |
| Total Assets | 915.53M | 925.67M | 913.17M | 904.95M | 907.44M |
|
|
|||||
| Total Accounts Payable | 26.21M | 37.45M | 22.16M | 31.24M | 32.00M |
| Total Accrued Expenses | 74.62M | 83.50M | 104.71M | 82.91M | 78.05M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 2.67M | 3.90M | 5.04M | 7.28M | 8.07M |
| Total Finance Division Other Current Liabilities | 3.35M | 4.57M | 6.45M | 4.36M | 11.03M |
| Total Other Current Liabilities | 3.35M | 4.57M | 6.45M | 4.36M | 11.03M |
| Total Current Liabilities | 106.85M | 129.42M | 138.36M | 125.79M | 129.16M |
|
|
|||||
| Total Current Liabilities | 106.85M | 129.42M | 138.36M | 125.79M | 129.16M |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 43.33M | 43.88M | 44.40M | 45.21M | 45.10M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 29.31M | 30.61M | 31.83M | 31.67M | 34.70M |
| Total Liabilities | 179.49M | 203.91M | 214.59M | 202.66M | 208.95M |
|
|
|||||
| Common Stock & APIC | 3.62B | 3.56B | 3.46B | 3.39B | 3.29B |
| Retained Earnings | -2.90B | -2.85B | -2.78B | -2.70B | -2.61B |
| Treasury Stock & Other | 13.08M | 12.65M | 16.44M | 16.10M | 20.86M |
| Total Common Equity | 736.04M | 721.75M | 698.58M | 702.29M | 698.49M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | 2.00K | 2.00K | 2.00K | 2.00K | 2.00K |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | 2.00K | 2.00K | 2.00K | 2.00K | 2.00K |
|
|
|||||
| Total Common Equity | 736.04M | 721.75M | 698.58M | 702.29M | 698.49M |
| Total Preferred Equity | 2.00K | 2.00K | 2.00K | 2.00K | 2.00K |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 736.05M | 721.75M | 698.58M | 702.29M | 698.49M |
|
|
|||||